The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia

Journal of the Neurological Sciences

Volumn 216, Issue 1, 2003, Pages 119-126

  Lojkowska, Wanda ^a   Ryglewicz, Danuta ^a   Jedrzejczak, Tomasz ^b   Minc, Sławomira ^a   Jakubowska, Teresa ^a   Jarosz, Halina ^a   Bochynska, Anna ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Rivastigmine; SPECT

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRONTAL CORTEX; HUMAN; MALE; MEDICAL EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE;

EID: 0242523117     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00229-6     Document Type: Article

References (44)

1. Francis T.P., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66:1999;137-147.
2. Jansen Steur E.N.H., Wevers A. The cholinergic system in Alzheimer's disease. Curr. Opin. Psychiatry. 15:2002;279-284.
3. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 61(1):2001;41-52.
4. Becker R.E., Moriearty P., Unni L. The second generation of cholisterase inhibitors: clinical and pharmacological effects. Becker R.E., Giacobini E. Cholinergic basis for Alzheimer therapy. 1991;263-296 Bishauser, Boston.
5. Thal L.J.et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology. 47:1996;1389-1395.
6. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
7. Rogers S.L., Farlow M.R., Rogers S.L., Mohs R.C.et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
8. Jann M.W. Rivastigmine, a new-generation cholinesterase inhibitor for treatment of Alzheimer's disease. Pharmacotherapy. 20(1):2000;1-12.
9. Grosberg G., Desai A. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert. Opin. Pharmacother. 2(4):2001;653-656.
10. Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 7:2000;159-169.
11. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., FCP(Neuro), Ding C. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology. 54:2000;2269-2276.
12. Jagust W.J., Budinger T.F., Reed B.R. The diagnosis of dementia with single photon emission computed tomography. Arch. Neurol. 44:1987;258-262.
13. O'Brien J.T., Eagger S., Syed G.M.S., Sahakian B.J., Levy R. A study of cerebral blood flow and cognitive performance in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 55:1992;1182-1187.
14. Scheltens P., Korf E.C. Contribution of neuroimaging in diagnosis of Alzheimer's disease and other dementias. Curr. Opin. Neurol. 13:2000;391-396.
15. Imran M.B., Kawashima R., Avata S. Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: correlation between neuropsychiatric evaluation and CBF images. J. Neurol. Neurosurg. Psychiatry. 24:1999;572-575.
16. Talbot P.R., Lloyd J.J., Snowden J.S., Neary D., Testa H.J. A clinical role for 99m Tc-HMPAO SPECT in the investigation of dementia? J. Neurol. Neurosurg. Psychol. 64:1998;306-313.
17. McKeith I.G., Bartholomev P.H., Irvine E.M. Single photon emission tomography in elderly patients with Alzheimer's disease and multi-infarct dementia. Regional uptake of technetium-labelled HMPAO related to clinical measurements. Br. J. Psychiatry. 163:1993;597-603.
18. Miekle R., Pietrzyk U., Jacobs A. HMPAO SPECT and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur. J. Nucl. 1994;1041-1043.
19. Pavics L., Grundwald F., Reichmann K. Regional cerebral blood flow single photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer's dementia. Eur. J. Med. 26:1999;239-244.
20. Lojkowska W., Ryglewicz D., Jedrzejczak T., Jarosz H., Minc S., Jakubowska T.et al. SPECT as a diagnostic test in the investigation of dementia. J. Neurol. Sci. 203-204:2002;215-219.
21. Costa D.C., Ell P.J. Clinician's guide to nuclear medicine, brain blood flow in neurology and psychiatry. 1991;Churchil Livingstone, Edinburgh.
22. Bell M.A., Decarli C., Culebras A., Korczyn A.D., Bogouslavsky J., Hartman A.et al. Vascular dementia: diagnostic criteria for research studies - a report of the NINDS-AIREN international workshop. Neurology. 43:1993;250-260.
23. Mc Khann G., Drachman D., Fostein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
24. Hachinsky V.C., Iliff L.D., Zilhka E., Du Boulay G.H., Mc Allliste V.L., Marshall J.et al. Cerebral blood flow in dementia. Arch. Neurol. 32:1975;632-637.
25. Roman G.C., Tatemichi T.K., Erkinjuntii T., Cummings J.L., Masdeu J.C., Garcia J.H.et al. Vascular dementia: diagnostic criteria for research studies - a report of the NINDS-AIREN international workshop. Neurology. 43:1993;250-260.
26. Gustafson L., Edvinsson L., Dahlgren N. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing regional cerebral blood flow (rCBF) measurement and EEG. Psychopharmacology. 93:1987;31-35.
27. Geaney D.P., Soper N., Shepstone B.J., Cowen P.J. Effects of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Lancet. 335:1990;1487-1490.
28. 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. Eur. Neurol. 29:1989;261-265.
29. Ebmeier K.P., Curran S.M., Dougal N.J., Murray C.L., Wyper D.J., Patterson J.et al. Effects of a single dose of the acetylcholinesterase inhibitor velancrine on recognition memory and regional cerebral blood flow in Alzheimer disease. Psychopharmacology (Berlin). 108(1-2):1992;103-109.
30. Warren S., Hier D.B., Pavel D. Visual form of Alzheimer disease and is response to anticholinesterase therapy. J. Neuroimaging. 8:1998;249-252.
31. Tune L.E., Tiseo P.J., Hofman J.M. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24 week study [abstract]. Neurology. 50:1998;A250.
32. Nakano S., Asada T., Matsuda H., Uno M., Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J. Nucl. Med. 42:2001;1441-1445.
33. Nobili F., Vitali P., Canfora M., Girtler N., De Leo C., Mariani G.et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin. Neurophysiol. 113(8):2002;1241-1248.
34. Nobili F., Koulibaly M., Vitali P., Migneco O., Mariani G., Ebmeier K.et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J. Nucl. Med. 43(8):2002;983-990.
35. Vennerica A., Shanks M.F., Staff R.T., Pestell S.J., Forbes K.E., Gemmel H.G.et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport. 13(1):2002;83-87.
36. Braida D., Sala M. Epstagmine: ten years of pharmacology, toxicology, pharmacokinetics and clinical studies. CNS Drug Rev. 7(4):2001 (Winter);369-386.
37. Nordberg A. PET studies and cholinergic therapy in Alzheimer disease. Rev. Neurol. (Paris). 155(Suppl. 4):1999;S53-S63.
38. van Dyck C.H., Robinson R., Cellar J., Smith E.O., Nelosn J.C., Arnsten A.F.et al. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer disease. Psychopharmacology (Berlin). 132(3):1997;217-226.
39. Sadoshima S., Ibayashi S., Fujii K., Nagao T., Sugimori H., Fujishima M. Inhibition of acetylcholinesterase modulates the autoregulation of cerebral blood flow and attenuates ischemic brain metabolism in hypertensive rats. J. Cereb. Blood Flow Metab. 15(5):1995;845-851.
40. Sato A., Sato Y. Cholinergic neural regulation cerebral blood flow. Alzheimer Dis. Assoc. Disord. 9(1):1995;28-38.
41. Sato A., Sato Y., Uchida S. Regulation of cerebral cortical blood flow by the basal forebrain cholinergic fibers and aging. Auton. Neurosci. 28; 96(1):2002;13-19.
42. Estrada C., Hamel E., Krause D.N. Biochemical evidence for cholinergic innervation of intracerebral blood vessels. Brain Res. 266:1983;261-270.
43. Maelicke A. The pharmacological rationale for treatment vascular dementia with galantamine (Reminyl). Int. J. Clin. Pract. (Suppl. 120):2001;24-28.
44. Mendez M.F., Yonesi F.L., Perryman K.M. Use of donepezil for vascular dementia: preliminary clinical experience. J. Neuropsychol. Clin. Neurosci. 11:1999;268-270.